

REDX PHARMA PLC
("Redx" or the "Company")

Redx Virtual R&D Day with Leading Experts and New Clinical Data for ROCK2 Inhibitor

Encouraging new data shows selective ROCK2 inhibitor RXC007 has an excellent safety and pharmacokinetic profile in ongoing Phase 1 study

RXC004 Phase 2 programme to commence in Q4 2021 in Wnt-ligand driven tumours

Redx's discovery engine targeting three new INDs by 2025

Alderley Park, UK, 11 October 2021 - Redx Pharma (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces it is hosting a Virtual R&D Day later today between 1:00pm-2:30pm BST (8:00am-9:30am EDT).

The R&D Day will feature updates from the Company's leadership team and presentations from leading experts in the fields of colorectal cancer and fibrosis. Focus will be on Redx's wholly owned lead product RXC004, a selective Porcupine inhibitor. Redx plans to commence a global Phase 2 monotherapy programme with RXC004 in three cancer types with Wnt-ligand dependent tumours: microsatellite stable metastatic colorectal cancer, pancreatic cancer and biliary tract cancer. RXC004 is also currently being investigated in a Phase 1 study in combination with the anti-PD-1 antibody nivolumab.

There will also be an update on the wholly owned selective ROCK2 inhibitor RXC007, being developed for idiopathic pulmonary fibrosis. Encouraging new clinical data from the ongoing RXC007 Phase 1 study* in healthy volunteers shows:

- An excellent safety and pharmacokinetic profile
- No adverse events following single dose of 2-40 milligram
- Pharmacokinetics as predicted from preclinical data
- Essentially linear exposure for 2-40 milligram
- Biologically relevant exposures achieved at higher doses
- At 40 milligram the half-life was approximately 11 hours, suitable for once-daily dosing

The R&D event includes presentations from leading experts:

- Professor Scott Kopetz, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
- Professor Gisli Jenkins, Faculty of Medicine, National Heart & Lung Institute, Imperial College London
- Professor Toby Maher, Professor of Medicine and Director of Interstitial Lung Disease, Keck School of Medicine, University of Southern California, Los Angeles

To register and receive a link to view the webcast, please email redxpharma@fticonsulting.com. A recording of the webcast will be available on Redx's website www.redxpharma.com following the event.

[*Clinicaltrials.gov](http://Clinicaltrials.gov) identifier NCT04931147; data cut-off date 14 September 2021

For further information, please contact:

Redx Pharma Plc T: +44 (0)1625 469 918

UK Headquarters

Lisa Anson, Chief Executive Officer
Karl Hård, Head of Investor Relations

k.hard@redxpharma.com

US Office

Peter Collum, Chief Financial Officer

SPARK Advisory Partners (Nominated Adviser) T: +44 (0)203 368 3550

Matt Davis/Adam Dawes

WG Partners LLP (Joint Broker) T: +44 (0)203 705 9330

Claes Spång/Nigel Birks/David Wilson

Panmure Gordon (UK) Limited (Joint Broker) T: +44 (0)207 886 2500

Rupert Dearden/Freddy Crossley/Emma Earl

FTI Consulting T: +44 (0)203 727 1000

Simon Conway/Ciara Martin

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept, before evaluating options for further development and potential value creation. Redx's lead oncology asset, the Porcupine inhibitor RXC004, is expected to commence a Phase 2 programme in H2 2021. The Company's selective ROCK2 inhibitor, RXC007, is in development for idiopathic pulmonary fibrosis and commenced a Phase 1 clinical study in June 2021 for which results are expected in 2022.

The Company has a strong track record of discovering new drug candidates through its core capability of converting medicinal chemistry insights into differentiated and commercially attractive drug candidates, with five proprietary or partnered assets in late pre-clinical or clinical development. One of those assets, a BTK inhibitor - pirtobrutinib/LOXO-305 - was sold to Loxo Oncology (now Eli Lilly) and is currently in Phase 3 clinical studies in chronic lymphocytic leukaemia. In addition, Redx has forged pre-clinical asset partnerships with other blue chip companies including AstraZeneca and Jazz Pharmaceuticals.

To subscribe to Email alerts from Redx, please visit:

www.redxpharma.com/investor-centre/email-alerts/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCFFFIVLILIL